Explore Medicare coverage limitations for Saxenda, a GLP-1 agonist approved for weight loss, and the implications for obesity drug access and insurance plan strategies.

CMS is considering a pilot program to cover GLP-1 drugs for obesity under Medicare and Medicaid, reversing earlier policy. This evolving coverage changes obesity drug access for patients and payers.